Mesenchymal Stem Cells Market

Mesenchymal Stem Cells Market (Products & Services: Product and Services; Source of Isolation: Bone Marrow, Adipose, Cord Blood, Peripheral Blood, Dental Pulp, and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2023-2031

Global Mesenchymal Stem Cells Market Outlook 2031

  • The global industry was valued at US$ 3.2 Bn in 2022
  • It is projected to grow at a CAGR of 12.7% from 2023 to 2031 and reach more than US$ 10.1 Bn by the end of 2031

Analysts’ Viewpoint

The global mesenchymal stem cells (MSCs) market witnessed steady growth in the past few years. MSCs have gained popularity in regenerative medicine, immunotherapy, and drug discovery due to unique characteristics such as self-renewal, differentiation potential, and immunomodulatory properties. Rise in prevalence of chronic diseases such as cancer, diabetes, and autoimmune disorders is expected to drive market expansion in the next few years. Furthermore, rise in patient preference for regenerative medicine is propelling market progress.

Increase in investment in research & development activities is projected to offer lucrative opportunities to market players. Companies are focusing on developing new products and technologies to expand product offerings and gain a competitive edge in the market.

Mesenchymal Stem Cells Market

Mesenchymal Stem Cells Market Introduction

Mesenchymal stem cells (MSCs) are a type of adult stem cell that can be found in various tissues in the body, including bone marrow, adipose tissue, and umbilical cord tissue. These are multipotent, which means they have the ability to differentiate into several different types of cell, such as bone cells, cartilage cells, and fat cells.

In addition to their differentiation potential, MSCs possess immunomodulatory properties. These can regulate the immune system by inhibiting the proliferation of T cells and activating regulatory T cells. This makes them an attractive candidate for the treatment of various autoimmune diseases and transplant rejection.

MSCs also secrete various growth factors and cytokines that are essential for tissue repair and regeneration. These factors can promote angiogenesis, reduce inflammation, and stimulate the growth and differentiation of other cells.

MSCs have gained attention in the past few years due to their unique properties such as self-renewal and multipotency. These cells have been used in various fields, including regenerative medicine, immunotherapy, and drug discovery.

Rise in Awareness about Regenerative Medicine

Regenerative medicine is a rapidly growing field that aims to restore or replace damaged or diseased tissues and organs in the body. The field is based on the principles of tissue engineering, stem cell biology, and transplantation biology. Regenerative medicine holds great promise for the treatment of various diseases and conditions, including cancer, heart disease, diabetes, and neurological disorders. Mesenchymal stem cells are a key component of several regenerative medicine therapies.

Rise in awareness about regenerative medicine and its potential benefits has led to increase in demand for MSCs. Patients are increasingly interested in regenerative medicine therapies due to the potential to provide long-lasting and curative treatments for various diseases and conditions. Furthermore, advancements in technology and scientific research have contributed to the growing interest in regenerative medicine. Development of new tools and techniques for tissue engineering, gene editing, and stem cell manipulation have led to the discovery of new applications for MSCs and other stem cells.

Increase in demand for MSCs has led to the development of new manufacturing processes and quality control standards to ensure the safety and efficacy of MSC-based therapies. This has also led to the creation of new jobs and business opportunities in the regenerative medicine industry.

Increase in Investment in Research & Development

Research & development (R&D) activities are critical for the advancement of any industry, and the mesenchymal stem cells (MSCs) market is no exception. Key players in the market are investing significantly in R&D activities to develop new products and technologies, which has led to the discovery of new applications for MSCs and improved manufacturing processes.

One of the primary goals of R&D activities in the MSCs market is to discover new applications for MSC-based therapies. MSCs have shown promise in the treatment of various diseases and conditions, including autoimmune disorders, cardiovascular diseases, and neurological disorders. By investing in R&D, companies are able to explore new applications for MSCs and develop innovative therapies that have the potential to improve patient outcomes.

R&D activities in the mesenchymal stem cells market are focused on improving manufacturing processes. This includes the development of new technologies for cell culture, expansion, and characterization, as well as the implementation of quality control standards to ensure the safety and efficacy of MSC-based therapies. Improved manufacturing processes have led to reduced costs and improved product quality, which has made MSC-based therapies more accessible to patients.

R&D activities in the market are also focused on improving the delivery of MSC-based therapies. This includes the development of new delivery methods, such as targeted delivery systems and gene-editing technologies, which can improve the efficacy and safety of MSC-based therapies. Investment in R&D activities in the MSCs market has also led to the creation of business opportunities.

Rise in Demand for MSC-based Products

In terms of products & services, the product segment dominated the global mesenchymal stem cells industry in 2022. The is ascribed to increase in demand for MSC-based products and availability of a range of products for various applications. MSC-based products are used in various fields, including regenerative medicine, drug discovery, and basic research. Demand for these products is expected to increase in the next few years. Development of new MSC-based products and technologies contributed to the growth of the product segment.

Lower Maintenance Cost and Multiple Uses of Allogenic MSC

Based on type, the allogenic segment accounted for the largest global mesenchymal stem cells market share in 2022. The segment includes MSCs derived from a donor, rather than from the patient's own cells (autologous). Growth of the allogenic segment can be attributed to lower cost and faster production time compared to autologous MSCs. Allogenic MSCs can be mass-produced and stored for future use, making them more readily available for clinical use. Furthermore, allogenic MSCs can be used in patients who do not have viable autologous MSCs or who require repeated treatments.

Surge in demand for MSC-based products and therapies in various applications, such as regenerative medicine, drug discovery, and basic research, has also contributed to the growth of the allogenic segment. Key players in the MSCs market are investing in the development of new allogenic MSC-based products and therapies to meet the growing demand.

Demand for Non-invasive and Painless Collection Procedure

In terms of source of isolation, the cord blood segment dominated the global market in 2022. This is ascribed to non-invasive and painless collection procedure compared to other sources of MSCs such as bone marrow. Cord blood contains a higher concentration of MSCs than other sources, making it an attractive option for cell-based therapies. Furthermore, cord blood MSCs are less likely to cause immune rejection as these are less mature and have not been exposed to environmental stimuli that could lead to immune recognition.

Rise in demand for MSC-based products and therapies in various applications, such as regenerative medicine, drug discovery, and basic research, contributed to the growth of the cord blood segment. Key players in the mesenchymal stem cells market are investing in the development of new cord blood MSC-based products and therapies to meet the growing demand from customers.

Increase in New Formulations and Delivery Methods of Drugs

Based on indication, the musculoskeletal diseases segment led the global mesenchymal stem cells market in 2022. MSCs have been shown to have therapeutic potential in the treatment of a range of musculoskeletal diseases, including osteoarthritis, osteoporosis, and rheumatoid arthritis. Growth of the segment can be attributed to high prevalence of musculoskeletal disorders globally, increase in the elderly population, and limitations of current treatments for these diseases. MSC-based therapies have shown promising results in preclinical and clinical trials for the treatment of musculoskeletal diseases, and their potential for regenerating damaged tissues and reducing inflammation has generated a lot of interest in the medical community.

Development of novel MSC-based products and technologies for the treatment of musculoskeletal diseases has also contributed to the growth of the musculoskeletal diseases segment. Key players in the mesenchymal stem cells market are investing in research & development activities to develop new and innovative MSC-based products and therapies for the treatment of musculoskeletal diseases.

Regional Outlook

As per mesenchymal stem cells market trends, North America accounted for the largest share of the global market in 2022. This is ascribed to presence of a large number of key players, favorable regulatory policies, and increase in investment in research & development activities.

North America is home to several leading biopharmaceutical companies that are actively involved in the development and commercialization of MSC-based products and therapies. These companies have a strong focus on innovation and are investing in research & development activities to develop new and improved MSC-based products and technologies. Furthermore, the region has a favorable regulatory environment for the development and commercialization of MSC-based products and therapies. Regulatory bodies such as the FDA in the U.S. have provided clear guidelines for the development and clinical evaluation of MSC-based products, which has helped to accelerate the approval process for these products.

The mesenchymal stem cells market in Asia Pacific is projected to grow at a rapid pace during the forecast period. The region has a large population base, rapidly growing economy, and increasing investment in healthcare infrastructure. China, Japan, South Korea, and India are the major markets for MSCs in the region. China is the largest market for MSCs, with a significant number of clinical trials and research studies being conducted. The Government of China has provided significant funding for the development of MSC-based products and therapies, which has helped to boost the growth of the MSCs market in the country.

Asia Pacific is also home to several key players, who are actively involved in the development and commercialization of MSC-based products and therapies. These companies are leveraging the region's large patient pool and favorable regulatory environment to expand their operations and increase their market share.

Analysis of Key Players

This report provides profiles of leading players operating in the global mesenchymal stem cells industry. These include Thermo Fisher Scientific, Inc., Cytiva (Danaher Corporation), FUJIFILM Irvine Scientific (FUJIFILM Corporation), Merck KGaA, Lonza Group Ltd., STEMCELL Technologies, Inc., Takara Bio, Inc., Sartorius AG, Miltenyi Biotec GmbH, and PromoCell GmbH. These players engage in merger & acquisition, strategic collaborations, and new product launches to expand presence and increase market share.

Key Developments in Global Mesenchymal Stem Cells Market

  • In November 2020, Japan-based pharmaceutical company Takeda announced collaboration with the global stem cell therapy company, Cynata Therapeutics, to develop an off-the-shelf mesenchymal stem cell therapy for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) induced acute respiratory distress syndrome (ARDS)
  • In February 2020, Pluristem Therapeutics announced that it received approval from the U.S. FDA to conduct a phase II trial of its placental-derived mesenchymal stem cell therapy for the treatment of acute respiratory distress syndrome (ARDS) associated with COVID-19
  • In May 2019, Mesoblast announced that it had completed phase III clinical trials for its allogeneic mesenchymal stem cell therapy for the treatment of chronic heart failure
  • In April 2019, Athersys announced that it had received approval from the Japanese Pharmaceuticals and Medical Devices Agency (PMDA) to conduct a phase III trial of its allogeneic mesenchymal stem cell therapy for the treatment of acute respiratory distress syndrome (ARDS)
  • In January 2019, TiGenix, announced that it received approval from the European Commission to market its allogeneic adipose-derived mesenchymal stem cell therapy for the treatment of complex perianal fistulas in patients with Crohn's disease.

The report profiles top players based on various factors including a company overview, financial summary, strategies, product portfolio, segments, and recent advancements in the market.

Global Mesenchymal Stem Cells Market Snapshot

Attribute

Detail

Size in 2022

US$ 3.2 Bn

Forecast (Value) in 2031

More than US$ 10.1 Bn

Growth Rate (CAGR)

12.7%

Forecast Period

2023–2031

Historical Data Available for

2017–2022

Quantitative Units

US$ Bn for Value

Market Analysis

It includes segment analysis as well as regional level analysis. Moreover, qualitative analysis includes drivers, restraints, opportunities, key trends, Porter’s Five Forces analysis, value chain analysis, and key trend analysis.

Competition Landscape

  • Market share analysis by company (2022)
  • Company profiles section includes overview, product portfolio, sales footprint, key subsidiaries or distributors, strategy & recent developments, and key financials

Format

Electronic (PDF) + Excel

Segmentation

  • Products & Services
    • Product
    • Workflow Type
    • Product Type
    • Services
  • Type
    • Autologous
    • Allogenic
  • Source of Isolation
    • Bone Marrow
    • Adipose
    • Cord Blood
    • Peripheral Blood
    • Dental Pulp
    • Others
  • Indication
    • Musculoskeletal Diseases
    • Cardiovascular Diseases
    • Neuro Disorders
    • Autoimmune Diseases
    • Cancer
    • GvHD
    • Pulmonary Diseases
    • Others

Regions Covered

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa

 Countries Covered

  • U.S.
  • Canada
  • Germany
  • U.K.
  • France
  • Italy
  • Spain
  • China
  • Japan
  • India
  • Australia & New Zealand
  • Rest of Asia Pacific
  • Brazil
  • Mexico
  • Rest of Latin America
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Companies Profiled

  • Thermo Fisher Scientific, Inc.
  • Cytiva (Danaher Corporation)
  • FUJIFILM Irvine Scientific (FUJIFILM Corporation)
  • Merck KGaA
  • Lonza Group Ltd.
  • STEMCELL Technologies, Inc.
  • Takara Bio, Inc.
  • Sartorius AG
  • Miltenyi Biotec GmbH and
  • PromoCell GmbH

Customization Scope

Available upon request

Pricing

Available upon request

Frequently Asked Questions

How big was the global mesenchymal stem cells market in 2022?

The global industry was valued at US$ 3.2 Bn in 2022.

How big will it be in 2031?

It is projected to reach more than US$ 10.1 Bn by 2031.

What will be the CAGR during the forecast period?

The CAGR is anticipated to be 12.7% from 2023 to 2031.

Which segment accounted for leading market share?

The allogenic segment held the largest share of the market in 2022.

Which region will account for major share during the forecast period?

North America is expected to account for significant market share during the forecast period.

Who are the prominent players in the market?

Thermo Fisher Scientific, Inc., Cytiva (Danaher Corporation), FUJIFILM Irvine Scientific (FUJIFILM Corporation), Merck KGaA, Lonza Group Ltd., STEMCELL Technologies, Inc., Takara Bio, Inc., Sartorius AG, Miltenyi Biotec GmbH, and PromoCell GmbH are the prominent players in the market.

    1. Preface

        1.1. Market Definition and Scope

        1.2. Market Segmentation

        1.3. Key Research Objectives

        1.4. Research Highlights

    2. Assumptions and Research Methodology

    3. Executive Summary: Global Mesenchymal Stem Cells Market

    4. Market Overview

        4.1. Introduction

        4.2. Overview

        4.3. Market Dynamics

            4.3.1. Drivers

            4.3.2. Restraints

            4.3.3. Opportunities

        4.4. Global Mesenchymal Stem Cells Market Analysis and Forecast, 2017–2031

    5. Key Insights

        5.1. Pipeline Analysis

        5.2. List Of Major Research Institutes Involved In Mesenchymal Stem Cells Studies

        5.3. Mesenchymal Stem Cells: Current Trends and Future Prospects in a Variety of Disease Conditions

        5.4. Regulatory Scenario by Region/globally

        5.5. COVID-19 Pandemic Impact on Industry

    6. Global Mesenchymal Stem Cells Market Analysis and Forecast, by Products & Services

        6.1. Introduction & Definition

        6.2. Key Findings / Developments

        6.3. Market Value Forecast, by Products & Services, 2017–2031

            6.3.1. Product

                6.3.1.1. Workflow Type

                6.3.1.2. Product Type

            6.3.2. Services

        6.4. Market Attractiveness Analysis, by Products & Services

    7. Global Mesenchymal Stem Cells Market Analysis and Forecast, by Type

        7.1. Introduction & Definition

        7.2. Key Findings / Developments

        7.3. Market Value Forecast, by Type, 2017–2031

            7.3.1. Autologous

            7.3.2. Allogenic

        7.4. Market Attractiveness Analysis, by Type

    8. Global Mesenchymal Stem Cells Market Analysis and Forecast, by Source of Isolation

        8.1. Introduction & Definition

        8.2. Key Findings / Developments

        8.3. Market Value Forecast, by Source of Isolation, 2017–2031

            8.3.1. Bone Marrow

                8.3.1.1. Adipose

                8.3.1.2. Cord Blood

                8.3.1.3. Peripheral Blood

            8.3.2. Dental Pulp

            8.3.3. Others (lung tissue, umbilical cord tissue, etc.)

        8.4. Market Attractiveness Analysis, by Source of Isolation

    9. Global Mesenchymal Stem Cells Market Analysis and Forecast, by Indication

        9.1. Introduction & Definition

        9.2. Key Findings / Developments

        9.3. Market Value Forecast, by Indication, 2017–2031

            9.3.1. Musculoskeletal Diseases

            9.3.2. Cardiovascular Diseases

            9.3.3. Neuro Disorders

            9.3.4. Autoimmune Diseases

            9.3.5. Cancer

            9.3.6. GvHD

            9.3.7. Pulmonary Diseases

            9.3.8. Others

        9.4. Market Attractiveness Analysis, by Indication

    10. Global Mesenchymal Stem Cells Market Analysis and Forecast, by Region

        10.1. Key Findings

        10.2. Market Value Forecast, by Region

            10.2.1. North America

            10.2.2. Europe

            10.2.3. Asia Pacific

            10.2.4. Latin America

            10.2.5. Middle East & Africa

        10.3. Market Attractiveness Analysis, by Region

    11. North America Mesenchymal Stem Cells Market Analysis and Forecast

        11.1. Introduction

            11.1.1. Key Findings

        11.2. Market Value Forecast, by Products & Services, 2017–2031

            11.2.1. Product

                11.2.1.1. Workflow Type

                11.2.1.2. Product Type

            11.2.2. Services

        11.3. Market Value Forecast, by Type, 2017–2031

            11.3.1. Autologous

            11.3.2. Allogenic

        11.4. Market Value Forecast, by Source of Isolation, 2017–2031

            11.4.1. Bone Marrow

                11.4.1.1. Adipose

                11.4.1.2. Cord Blood

                11.4.1.3. Peripheral Blood

            11.4.2. Dental Pulp

            11.4.3. Others (lung tissue, umbilical cord tissue, etc.)

        11.5. Market Value Forecast, by Indication , 2017–2031

            11.5.1. Musculoskeletal Diseases

            11.5.2. Cardiovascular Diseases

            11.5.3. Neuro Disorders

            11.5.4. Autoimmune Diseases

            11.5.5. Cancer

            11.5.6. GvHD

            11.5.7. Pulmonary Diseases

            11.5.8. Others

        11.6. Market Value Forecast, by Country, 2017–2031

            11.6.1. U.S.

            11.6.2. Canada

        11.7. Market Attractiveness Analysis

            11.7.1. By Product

            11.7.2. By Type

            11.7.3. By Source of Isolation

            11.7.4. By Indication

            11.7.5. By Country

    12. Europe Mesenchymal Stem Cells Market Analysis and Forecast

        12.1. Introduction

            12.1.1. Key Findings

        12.2. Market Value Forecast, by Products & Services, 2017–2031

            12.2.1. Product

                12.2.1.1. Workflow Type

                12.2.1.2. Product Type

            12.2.2. Services

        12.3. Market Value Forecast, by Type, 2017–2031

            12.3.1. Autologous

            12.3.2. Allogenic

        12.4. Market Value Forecast, by Source of Isolation, 2017–2031

            12.4.1. Bone Marrow

                12.4.1.1. Adipose

                12.4.1.2. Cord Blood

                12.4.1.3. Peripheral Blood

            12.4.2. Dental Pulp

            12.4.3. Others (lung tissue, umbilical cord tissue, etc.)

        12.5. Market Value Forecast, by Indication , 2017–2031

            12.5.1. Musculoskeletal Diseases

            12.5.2. Cardiovascular Diseases

            12.5.3. Neuro Disorders

            12.5.4. Autoimmune Diseases

            12.5.5. Cancer

            12.5.6. GvHD

            12.5.7. Pulmonary Diseases

            12.5.8. Others

        12.6. Market Value Forecast, by Country/Sub-region, 2017–2031

            12.6.1. Germany

            12.6.2. U.K.

            12.6.3. France

            12.6.4. Italy

            12.6.5. Spain

            12.6.6. Rest of Europe

        12.7. Market Attractiveness Analysis

            12.7.1. By Product

            12.7.2. By Type

            12.7.3. By Source of Isolation

            12.7.4. By Indication

            12.7.5. By Country/Sub-region

    13. Asia Pacific Mesenchymal Stem Cells Market Analysis and Forecast

        13.1. Introduction

            13.1.1. Key Findings

        13.2. Market Value Forecast, by Products & Services, 2017–2031

            13.2.1. Product

                13.2.1.1. Workflow Type

                13.2.1.2. Product Type

            13.2.2. Services

        13.3. Market Value Forecast, by Type, 2017–2031

            13.3.1. Autologous

            13.3.2. Allogenic

        13.4. Market Value Forecast, by Source of Isolation, 2017–2031

            13.4.1. Bone Marrow

                13.4.1.1. Adipose

                13.4.1.2. Cord Blood

                13.4.1.3. Peripheral Blood

            13.4.2. Dental Pulp

            13.4.3. Others (lung tissue, umbilical cord tissue, etc.)

        13.5. Market Value Forecast, by Indication , 2017–2031

            13.5.1. Musculoskeletal Diseases

            13.5.2. Cardiovascular Diseases

            13.5.3. Neuro Disorders

            13.5.4. Autoimmune Diseases

            13.5.5. Cancer

            13.5.6. GvHD

            13.5.7. Pulmonary Diseases

            13.5.8. Others

        13.6. Market Value Forecast, by Country/Sub-region, 2017–2031

            13.6.1. China

            13.6.2. Japan

            13.6.3. India

            13.6.4. South Korea

            13.6.5. Rest of Asia Pacific

        13.7. Market Attractiveness Analysis

            13.7.1. By Product

            13.7.2. By Type

            13.7.3. By Source of Isolation

            13.7.4. By Indication

            13.7.5. By Country/Sub-region

    14. Latin America Mesenchymal Stem Cells Market Analysis and Forecast

        14.1. Introduction

            14.1.1. Key Findings

        14.2. Market Value Forecast, by Products & Services, 2017–2031

            14.2.1. Product

                14.2.1.1. Workflow Type

                14.2.1.2. Product Type

            14.2.2. Services

        14.3. Market Value Forecast, by Type, 2017–2031

            14.3.1. Autologous

            14.3.2. Allogenic

        14.4. Market Value Forecast, by Source of Isolation, 2017–2031

            14.4.1. Bone Marrow

                14.4.1.1. Adipose

                14.4.1.2. Cord Blood

                14.4.1.3. Peripheral Blood

            14.4.2. Dental Pulp

            14.4.3. Others (lung tissue, umbilical cord tissue, etc.)

        14.5. Market Value Forecast, by Indication , 2017–2031

            14.5.1. Musculoskeletal Diseases

            14.5.2. Cardiovascular Diseases

            14.5.3. Neuro Disorders

            14.5.4. Autoimmune Diseases

            14.5.5. Cancer

            14.5.6. GvHD

            14.5.7. Pulmonary Diseases

            14.5.8. Others

        14.6. Market Value Forecast, by Country/Sub-region, 2017–2031

            14.6.1. Brazil

            14.6.2. Mexico

            14.6.3. Rest of Latin America

        14.7. Market Attractiveness Analysis

            14.7.1. By Product

            14.7.2. By Type

            14.7.3. By Source of Isolation

            14.7.4. By Indication

            14.7.5. By Country/Sub-region

    15. Middle East & Africa Mesenchymal Stem Cells Market Analysis and Forecast

        15.1. Introduction

            15.1.1. Key Findings

        15.2. Market Value Forecast, by Products & Services, 2017–2031

            15.2.1. Product

                15.2.1.1. Workflow Type

                15.2.1.2. Product Type

            15.2.2. Services

        15.3. Market Value Forecast, by Type, 2017–2031

            15.3.1. Autologous

            15.3.2. Allogenic

        15.4. Market Value Forecast, by Source of Isolation, 2017–2031

            15.4.1. Bone Marrow

                15.4.1.1. Adipose

                15.4.1.2. Cord Blood

                15.4.1.3. Peripheral Blood

            15.4.2. Dental Pulp

            15.4.3. Others (lung tissue, umbilical cord tissue, etc.)

        15.5. Market Value Forecast, by Indication, 2017–2031

            15.5.1. Musculoskeletal Diseases

            15.5.2. Cardiovascular Diseases

            15.5.3. Neuro Disorders

            15.5.4. Autoimmune Diseases

            15.5.5. Cancer

            15.5.6. GvHD

            15.5.7. Pulmonary Diseases

            15.5.8. Others

        15.6. Market Value Forecast, by Country/Sub-region, 2017–2031

            15.6.1. GCC Countries

            15.6.2. South Africa

            15.6.3. Rest of Middle East & Africa

        15.7. Market Attractiveness Analysis

            15.7.1. By Product

            15.7.2. By Type

            15.7.3. By Source of Isolation

            15.7.4. By Indication

            15.7.5. By Country/Sub-region

    16. Competition Landscape

        16.1. Market Player - Competition Matrix (by tier and size of companies)

        16.2. Market Share Analysis, by Company, 2021

        16.3. Company Profiles

            16.3.1. Thermo Fisher Scientific, Inc.

                16.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)

                16.3.1.2. Product Portfolio

                16.3.1.3. Financial Overview

                16.3.1.4. SWOT Analysis

                16.3.1.5. Strategic Overview

            16.3.2. Cytiva (Danaher Corporation)

                16.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)

                16.3.2.2. Product Portfolio

                16.3.2.3. Financial Overview

                16.3.2.4. SWOT Analysis

                16.3.2.5. Strategic Overview

            16.3.3. FUJIFILM Irvine Scientific (FUJIFILM Corporation)

                16.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)

                16.3.3.2. Product Portfolio

                16.3.3.3. Financial Overview

                16.3.3.4. SWOT Analysis

                16.3.3.5. Strategic Overview

            16.3.4. Merck KGaA

                16.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)

                16.3.4.2. Product Portfolio

                16.3.4.3. Financial Overview

                16.3.4.4. SWOT Analysis

                16.3.4.5. Strategic Overview

            16.3.5. Lonza Group Ltd.

                16.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)

                16.3.5.2. Product Portfolio

                16.3.5.3. Financial Overview

                16.3.5.4. SWOT Analysis

                16.3.5.5. Strategic Overview

            16.3.6. STEMCELL Technologies, Inc.

                16.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)

                16.3.6.2. Product Portfolio

                16.3.6.3. Financial Overview

                16.3.6.4. SWOT Analysis

                16.3.6.5. Strategic Overview

            16.3.7. Takara Bio, Inc.

                16.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)

                16.3.7.2. Product Portfolio

                16.3.7.3. Financial Overview

                16.3.7.4. SWOT Analysis

                16.3.7.5. Strategic Overview

            16.3.8. Sartorius AG

                16.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)

                16.3.8.2. Product Portfolio

                16.3.8.3. Financial Overview

                16.3.8.4. SWOT Analysis

                16.3.8.5. Strategic Overview

            16.3.9. Miltenyi Biotec GmbH

                16.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)

                16.3.9.2. Product Portfolio

                16.3.9.3. Financial Overview

                16.3.9.4. SWOT Analysis

                16.3.9.5. Strategic Overview

            16.3.10. PromoCell GmbH

                16.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)

                16.3.10.2. Product Portfolio

                16.3.10.3. Financial Overview

                16.3.10.4. SWOT Analysis

                16.3.10.5. Strategic Overview

    List of Tables

    Table 01: Global Mesenchymal Stem Cells Market Value (US$ Mn) Forecast, by Products & Services, 2017–2032

    Table 02: Global Mesenchymal Stem Cells Market Value (US$ Mn) Forecast, by Product, 2017–2032

    Table 03: Global Mesenchymal Stem Cells Market Value (US$ Mn) Forecast, by Type, 2017–2032

    Table 04: Global Mesenchymal Stem Cells Market Value (US$ Mn) Forecast, by Source of Isolation, 2017‒2032

    Table 05: Global Mesenchymal Stem Cells Market Value (US$ Mn) Forecast, by Indication, 2017–2032

    Table 06: Global Mesenchymal Stem Cells Market Value (US$ Mn) Forecast, by Region, 2017–2032

    Table 07: North America Mesenchymal Stem Cells Market Value (US$ Mn) Forecast, by Country, 2017–2032

    Table 08: North America Mesenchymal Stem Cells Market Value (US$ Mn) Forecast, by Products & Services, 2017–2032

    Table 09: North America Mesenchymal Stem Cells Market Value (US$ Mn) Forecast, by Product, 2017–2032

    Table 10: North America Mesenchymal Stem Cells Market Value (US$ Mn) Forecast, by Type, 2017–2032

    Table 11: North America Mesenchymal Stem Cells Market Value (US$ Mn) Forecast, by Source of Isolation, 2017‒2031

    Table 12: North America Mesenchymal Stem Cells Market Value (US$ Mn) Forecast, by Indication, 2017–2032

    Table 13: Europe Mesenchymal Stem Cells Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2032

    Table 14: Europe Mesenchymal Stem Cells Market Value (US$ Mn) Forecast, by Products & Services, 2017–2032

    Table 15: Europe Mesenchymal Stem Cells Market Value (US$ Mn) Forecast, by Product, 2017–2032

    Table 16: Europe Mesenchymal Stem Cells Market Value (US$ Mn) Forecast, by Type, 2017–2032

    Table 17: Europe Mesenchymal Stem Cells Market Value (US$ Mn) Forecast, by Source of Isolation, 2017‒2031

    Table 18: Europe Mesenchymal Stem Cells Market Value (US$ Mn) Forecast, by Indication, 2017–2032

    Table 19: Asia Pacific Mesenchymal Stem Cells Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2032

    Table 20: Asia Pacific Mesenchymal Stem Cells Market Value (US$ Mn) Forecast, by Products & Services, 2017–2032

    Table 21: Asia Pacific Mesenchymal Stem Cells Market Value (US$ Mn) Forecast, by Product, 2017–2032

    Table 22: Asia Pacific Mesenchymal Stem Cells Market Value (US$ Mn) Forecast, by Type, 2017–2032

    Table 23: Asia Pacific Mesenchymal Stem Cells Market Value (US$ Mn) Forecast, by Source of Isolation, 2017‒2031

    Table 24: Asia Pacific Mesenchymal Stem Cells Market Value (US$ Mn) Forecast, by Indication, 2017–2032

    Table 25: Latin America Mesenchymal Stem Cells Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2032

    Table 26: Latin America Mesenchymal Stem Cells Market Value (US$ Mn) Forecast, by Products & Services, 2017–2032

    Table 27: Latin America Mesenchymal Stem Cells Market Value (US$ Mn) Forecast, by Product, 2017–2032

    Table 28: Latin America Mesenchymal Stem Cells Market Value (US$ Mn) Forecast, by Type, 2017–2032

    Table 29: Latin America Mesenchymal Stem Cells Market Value (US$ Mn) Forecast, by Source of Isolation, 2017‒2031

    Table 30: Latin America Mesenchymal Stem Cells Market Value (US$ Mn) Forecast, by Indication, 2017–2032

    Table 31: Middle East & Africa Mesenchymal Stem Cells Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2032

    Table 32: Middle East & Africa Mesenchymal Stem Cells Market Value (US$ Mn) Forecast, by Products & Services, 2017–2032

    Table 33: Middle East & Africa Mesenchymal Stem Cells Market Value (US$ Mn) Forecast, by Product, 2017–2032

    Table 34: Middle East & Africa Mesenchymal Stem Cells Market Value (US$ Mn) Forecast, by Type, 2017–2032

    Table 35: Middle East & Africa Mesenchymal Stem Cells Market Value (US$ Mn) Forecast, by Source of Isolation, 2017‒2031

    Table 36: Middle East & Africa Mesenchymal Stem Cells Market Value (US$ Mn) Forecast, by Indication, 2017–2032

    List of Figures

    Figure 01: Global Mesenchymal Stem Cells Market Value (US$ Mn) Forecast, 2017–2032

    Figure 02: Global Mesenchymal Stem Cells Market Value Share, by Products & Services, 2022

    Figure 03: Global Mesenchymal Stem Cells Market Value Share, by Type, 2022

    Figure 04: Global Mesenchymal Stem Cells Market Value Share, by Source of Isolation, 2022

    Figure 05: Global Mesenchymal Stem Cells Market Value Share, by Indication, 2022

    Figure 06: Global Mesenchymal Stem Cells Market Value Share Analysis, by Products & Services, 2022 and 2032

    Figure 07: Global Mesenchymal Stem Cells Market Attractiveness Analysis, by Products & Services, 2023–2032

    Figure 08: Global Mesenchymal Stem Cells Market Revenue (US$ Mn), by Product, 2017–2032

    Figure 09: Global Mesenchymal Stem Cells Market Revenue (US$ Mn), by Services, 2017–2032

    Figure 10: Global Mesenchymal Stem Cells Market Value Share Analysis, by Type, 2022 and 2032

    Figure 11: Global Mesenchymal Stem Cells Market Attractiveness Analysis, by Type, 2023–2032

    Figure 12: Global Mesenchymal Stem Cells Market Revenue (US$ Mn), by Autologous, 2017–2032

    Figure 13: Global Mesenchymal Stem Cells Market Revenue (US$ Mn), by Allogenic, 2017–2032

    Figure 14: Global Mesenchymal Stem Cells Market Value Share Analysis, by Source of Isolation, 2022 and 2032

    Figure 15: Global Mesenchymal Stem Cells Market Attractiveness Analysis, by Source of Isolation 2023–2032

    Figure 16: Global Mesenchymal Stem Cells Market Value Share Analysis, by Indication, 2022 and 2032

    Figure 17: Global Mesenchymal Stem Cells Market Attractiveness Analysis, by Indication, 2023–2032

    Figure 18: Global Mesenchymal Stem Cells Market Value Share Analysis, by Region, 2022 and 2032

    Figure 19: Global Mesenchymal Stem Cells Market Attractiveness Analysis, by Region, 2023–2032

    Figure 20: North America Mesenchymal Stem Cells Market Value (US$ Mn) Forecast, 2017–2032

    Figure 21: North America Mesenchymal Stem Cells Market Value Share Analysis, by Country, 2022 and 2032

    Figure 22: North America Mesenchymal Stem Cells Market Attractiveness Analysis, by Country, 2023–2032

    Figure 23: North America Mesenchymal Stem Cells Market Value Share Analysis, by Products & Services, 2022 and 2032

    Figure 24: North America Mesenchymal Stem Cells Market Attractiveness Analysis, by Products & Services, 2023–2032

    Figure 25: North America Mesenchymal Stem Cells Market Value Share Analysis, by Type, 2022 and 2032

    Figure 26: North America Mesenchymal Stem Cells Market Attractiveness Analysis, by Type, 2023–2032

    Figure 27: North America Mesenchymal Stem Cells Market Value Share Analysis, by Source of Isolation, 2022 and 2032

    Figure 28: North America Mesenchymal Stem Cells Market Attractiveness Analysis, by Source of Isolation 2023–2032

    Figure 29: North America Mesenchymal Stem Cells Market Value Share Analysis, by Indication, 2022 and 2032

    Figure 30: North America Mesenchymal Stem Cells Market Attractiveness Analysis, Indication, 2023–2032

    Figure 31: Europe Mesenchymal Stem Cells Market Value (US$ Mn) Forecast, 2017–2032

    Figure 32: Europe Mesenchymal Stem Cells Market Value Share Analysis, by Country/Sub-region, 2022 and 2032

    Figure 33: Europe Mesenchymal Stem Cells Market Attractiveness Analysis, by Country/Sub-region, 2023–2032

    Figure 34: Europe Mesenchymal Stem Cells Market Value Share Analysis, by Products & Services, 2022 and 2032

    Figure 35: Europe Mesenchymal Stem Cells Market Attractiveness Analysis, by Products & Services, 2023–2032

    Figure 36: Europe Mesenchymal Stem Cells Market Value Share Analysis, by Type, 2022 and 2032

    Figure 37: Europe Mesenchymal Stem Cells Market Attractiveness Analysis, by Type, 2023–2032

    Figure 38: Europe Mesenchymal Stem Cells Market Value Share Analysis, by Source of Isolation, 2022 and 2032

    Figure 39: Europe Mesenchymal Stem Cells Market Attractiveness Analysis, by Source of Isolation 2023–2032

    Figure 40: Europe Mesenchymal Stem Cells Market Value Share Analysis, by Indication, 2022 and 2032

    Figure 41: Europe Mesenchymal Stem Cells Market Attractiveness Analysis, Indication, 2023–2032

    Figure 42: Asia Pacific Mesenchymal Stem Cells Market Value (US$ Mn) Forecast, 2017–2032

    Figure 43: Asia Pacific Mesenchymal Stem Cells Market Value Share Analysis, by Country/Sub-region, 2022 and 2032

    Figure 44: Asia Pacific Mesenchymal Stem Cells Market Attractiveness Analysis, by Country/Sub-region, 2023–2032

    Figure 45: Asia Pacific Mesenchymal Stem Cells Market Value Share Analysis, by Products & Services, 2022 and 2032

    Figure 46: Asia Pacific Mesenchymal Stem Cells Market Attractiveness Analysis, by Products & Services, 2023–2032

    Figure 47: Asia Pacific Mesenchymal Stem Cells Market Value Share Analysis, by Type, 2022 and 2032

    Figure 48: Asia Pacific Mesenchymal Stem Cells Market Attractiveness Analysis, by Type, 2023–2032

    Figure 49: Asia Pacific Mesenchymal Stem Cells Market Value Share Analysis, by Source of Isolation, 2022 and 2032

    Figure 50: Asia Pacific Mesenchymal Stem Cells Market Attractiveness Analysis, by Source of Isolation 2023–2032

    Figure 51: Asia Pacific Mesenchymal Stem Cells Market Value Share Analysis, by Indication, 2022 and 2032

    Figure 52: Asia Pacific Mesenchymal Stem Cells Market Attractiveness Analysis, Indication, 2023–2032

    Figure 53: Latin America Mesenchymal Stem Cells Market Value (US$ Mn) Forecast, 2017–2032

    Figure 54: Latin America Mesenchymal Stem Cells Market Value Share Analysis, by Country/Sub-region, 2022 and 2032

    Figure 55: Latin America Mesenchymal Stem Cells Market Attractiveness Analysis, by Country/Sub-region, 2023–2032

    Figure 56: Latin America Mesenchymal Stem Cells Market Value Share Analysis, by Products & Services, 2022 and 2032

    Figure 57: Latin America Mesenchymal Stem Cells Market Attractiveness Analysis, by Products & Services, 2023–2032

    Figure 58: Latin America Mesenchymal Stem Cells Market Value Share Analysis, by Type, 2022 and 2032

    Figure 59: Latin America Mesenchymal Stem Cells Market Attractiveness Analysis, Type, 2023–2032

    Figure 60: Latin America Mesenchymal Stem Cells Market Value Share Analysis, by Source of Isolation, 2022 and 2032

    Figure 61: Latin America Mesenchymal Stem Cells Market Attractiveness Analysis, Source of Isolation, 2023–2032

    Figure 62: Latin America Mesenchymal Stem Cells Market Value Share Analysis, by Indication, 2022 and 2032

    Figure 63: Latin America Mesenchymal Stem Cells Market Attractiveness Analysis, Indication, 2023–2032

    Figure 64: Middle East & Africa Mesenchymal Stem Cells Market Value (US$ Mn) Forecast, 2017–2032

    Figure 65: Middle East & Africa Mesenchymal Stem Cells Market Value Share Analysis, by Country/Sub-region, 2022 and 2032

    Figure 66: Middle East & Africa Mesenchymal Stem Cells Market Attractiveness Analysis, by Country/Sub-region, 2023–2032

    Figure 67: Middle East & Africa Mesenchymal Stem Cells Market Value Share Analysis, by Products & Services, 2022 and 2032

    Figure 68: Middle East & Africa Mesenchymal Stem Cells Market Attractiveness Analysis, by Products & Services, 2023–2032

    Figure 69: Middle East & Africa Mesenchymal Stem Cells Market Value Share Analysis, by Type, 2022 and 2032

    Figure 70: Middle East & Africa Mesenchymal Stem Cells Market Attractiveness Analysis, by Type, 2023–2032

    Figure 71: Middle East & Africa Mesenchymal Stem Cells Market Value Share Analysis, by Source of Isolation, 2022 and 2032

    Figure 72: Middle East & Africa Mesenchymal Stem Cells Market Attractiveness Analysis, by Source of Isolation, 2023–2032

    Figure 73: Middle East & Africa Mesenchymal Stem Cells Market Value Share Analysis, by Indication, 2022 and 2032

    Figure 74: Middle East & Africa Mesenchymal Stem Cells Market Attractiveness Analysis, by Indication, 2023–2032

Copyright © Transparency Market Research, Inc. All Rights reserved